What is HC Wainwright’s Estimate for IONS FY2027 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Research analysts at HC Wainwright issued their FY2027 EPS estimates for Ionis Pharmaceuticals in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings of ($0.35) per share for the year. HC Wainwright currently has a “Buy” rating and a $120.00 target price on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.50) per share.

A number of other equities research analysts also recently commented on the company. Needham & Company LLC lifted their price objective on Ionis Pharmaceuticals from $103.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a research report on Thursday, January 22nd. Royal Bank Of Canada restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Wednesday, February 25th. Bank of America upped their price objective on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Morgan Stanley set a $95.00 price objective on shares of Ionis Pharmaceuticals and gave the stock an “overweight” rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $89.60.

Ionis Pharmaceuticals Trading Up 4.3%

Shares of Ionis Pharmaceuticals stock opened at $72.70 on Thursday. Ionis Pharmaceuticals has a fifty-two week low of $23.95 and a fifty-two week high of $86.74. The firm has a market cap of $12.01 billion, a PE ratio of -29.79 and a beta of 0.31. The business’s fifty day moving average is $79.05 and its two-hundred day moving average is $75.57. The company has a quick ratio of 3.81, a current ratio of 3.83 and a debt-to-equity ratio of 2.76.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 25th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.18). The firm had revenue of $203.33 million for the quarter, compared to analyst estimates of $156.07 million. Ionis Pharmaceuticals had a negative return on equity of 68.82% and a negative net margin of 40.36%.The firm’s revenue was down 10.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.66) EPS.

Insider Activity at Ionis Pharmaceuticals

In other news, EVP Elizabeth L. Hougen sold 10,172 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $73.21, for a total value of $744,692.12. Following the transaction, the executive vice president directly owned 82,660 shares in the company, valued at $6,051,538.60. This trade represents a 10.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Brett P. Monia sold 34,103 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $75.92, for a total value of $2,589,099.76. Following the completion of the transaction, the chief executive officer directly owned 242,662 shares in the company, valued at $18,422,899.04. This represents a 12.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,035,882 shares of company stock valued at $80,492,247 over the last three months. Insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. raised its stake in shares of Ionis Pharmaceuticals by 72.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 652,518 shares of the company’s stock valued at $19,686,000 after acquiring an additional 274,310 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Ionis Pharmaceuticals by 6.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 659,435 shares of the company’s stock worth $19,895,000 after purchasing an additional 39,794 shares during the period. Focus Partners Wealth increased its holdings in Ionis Pharmaceuticals by 30.1% in the 1st quarter. Focus Partners Wealth now owns 9,832 shares of the company’s stock valued at $297,000 after purchasing an additional 2,277 shares in the last quarter. Creative Planning increased its holdings in Ionis Pharmaceuticals by 47.5% in the 2nd quarter. Creative Planning now owns 53,289 shares of the company’s stock valued at $2,105,000 after purchasing an additional 17,167 shares in the last quarter. Finally, Swiss National Bank raised its position in Ionis Pharmaceuticals by 4.8% in the second quarter. Swiss National Bank now owns 288,600 shares of the company’s stock valued at $11,403,000 after purchasing an additional 13,300 shares during the period. 93.86% of the stock is currently owned by hedge funds and other institutional investors.

Key Ionis Pharmaceuticals News

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $120 and maintained a “buy” rating — implying roughly 65% upside from the recent reference price; this is a strong vote of confidence in Ionis’ pipeline and likely helped lift sentiment. HC Wainwright PT Raise
• Positive Sentiment: Needham & Company increased its price target to $105 and reiterated a “buy” rating — another analyst upgrade that supports higher share-price expectations. Needham PT Raise
• Positive Sentiment: The FDA granted priority review to Ionis’ NDA for zilganersen for Alexander disease, setting a Sept. 22, 2026 decision date — a meaningful regulatory catalyst since priority review accelerates the timeline and reflects the agency’s view of potential benefit. FDA Priority Review for Zilganersen
• Neutral Sentiment: Short-interest reports posted this week show zero shares / zero days-to-cover data and flagged increases as NaN — likely a reporting/data anomaly rather than a meaningful change to short positioning. Investors should watch for corrected data if short activity is a concern.
• Negative Sentiment: EVP Eugene Schneider sold 5,812 shares (filed sale, avg price ~$70.97) — insider selling can be perceived negatively, though the executive still holds a large position. The size and timing may temper enthusiasm for some investors. Insider Sale

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.